Tradr 2X Long GS Daily ETF

Algorhythm

Jiade

Moolec Science SA

Nuveen Real Asset Income and Growth Fund

Atomera

AIM ImmunoTech

Splash Beverage

GraniteShares 2x Long RIVN Daily ETF

Founder

Vivopower

LABD

ARKG

SBIO

<p>IDEXX Laboratories Inc. (IDXX) shares fell 1.10% to $632.56 on Tuesday, marking the sixth consecutive day of losses. The stock is now 17.85% below its 52-week high of $769.98. In contrast, competitors like Johnson & Johnson (JNJ) and Medtronic PLC (MDT) saw gains of 1.02% and 0.46%, respectively. The overall market also declined, with the S&P 500 down 0.84%. Trading volume for IDXX was 632,848, surpassing its 50-day average of 547,981.</p>

Dow Jones

SPDR S&P Health Equip

SPDR S&P Biotech

Direxion S&P Biotech Bear 3X

First Trust NYSE Arca Biotech Index Fd

Ark Genomic Revolution ETF

iShares US Medical Devices

IDEXX Labs

iShares Genomics Immunology and Healthcare ETF

Health Care Select Sector SPDR

VG Health

iShares US Pharma

VanEck Biotech ETF

iShares Global Healthcare

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

IDEXX Laboratories Inc. Stock Underperforms Tuesday When Compared To Competitors

<p>Pfizer Inc. announced positive results from its Phase 2b VESPER-3 study for PF-08653944, an ultra-long-acting injectable GLP-1 receptor agonist. The study showed significant weight loss of up to 12.3% at 28 weeks with a switch from weekly to monthly dosing, maintaining a favorable safety profile. Pfizer plans to advance 10 Phase 3 trials for PF-08653944 in 2026, aiming to address obesity treatment gaps. The results reinforce confidence in the drug's efficacy and tolerability, with a higher monthly dose expected in future studies.</p>

- Pfizer announced positive results from the Phase 2b VESPER-3 study for its obesity treatment, PF-08653944 (PF’3944), demonstrating a statistically significant 12.3% weight reduction at 28 weeks.  
- The study shows that weight loss continued after switching from weekly to monthly dosing, with a favorable safety profile observed.  
- Pfizer plans to initiate 10 Phase 3 trials in 2026 as part of a robust clinical development program targeting obesity.

StockTitan

Invesco Nasdaq Biotechnology ETF

Direxion Daily Biotech Top 5 Bull 2X ETF

Pfizer

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

Pfizer’s Ultra-Long-Acting Injectable GLP-1 RA Shows Robust and Continued Weight Loss with Monthly Dosing in Phase 2b Trial | PFE Stock News

Tradr 2X Long GS Daily ETF(GSX.US)

IDEXX Laboratories Inc. Stock Underperforms Tuesday When Compared To Competitors

Pfizer’s Ultra-Long-Acting Injectable GLP-1 RA Shows Robust and Continued Weight Loss with Monthly Dosing in Phase 2b Trial | PFE Stock News